Scroll for more



Jason Meyenburg
Chief Commercial Officer

Mr. Meyenburg became our Chief Commercial Officer in April 2017, following Sucampo Pharmaceuticals’ acquisition of Vtesse Inc. Prior to joining Vtesse, Jason was Senior Vice President, Commercial, The Americas at Alexion Pharmaceuticals where he led operations in the U.S. and Latin America including responsibility across hematology, nephrology and metabolic disorder businesses. Jason held roles of increasing responsibility in Commercial at Alexion opening new markets in Europe, Middle East, Africa and Japan as well as roles in the development of Alexion’s pipeline.

Jason holds a Bachelor of Science in Biochemistry from the University of Maryland and a Master’s of Business Administration from Duke University’s Fuqua School of Business

Contact Us
Tel: +1-301-961-3400

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.